Clinical Verification Status
Completed Protocol - Worked as Intended
Nominal Total Dose
78.0Gy
Tumor EQD2 (α/β 1.5)
81.25Gy
Tumor Control (TCP)
92.4%
Normal Tissue Complication (NTCP)
4.8%
Interactive Daily Delivery Simulator
Step through daily fractions or simulate automated linear accelerator delivery
LINAC 6MV
PROSTATE PTV
Current: Fraction 39 of 39
Delivered Dose: 78.0 / 78.0 Gy
Dose-Response Relationships (Linear-Quadratic Model)
Sigmoidal Poisson/Logit
Tumor Control Probability (TCP)
Late Rectal Toxicity Risk (NTCP)
Planned Operating Point
Fractionation Regimens Comparison
RTOG / ASTRO Clinical Evidence
| Regimen Strategy | Prescription | Overall Time | EQD2 (Tumor) | Estimated TCP | Estimated NTCP |
|---|---|---|---|---|---|
| Standard Fractionation (Representative) | 78.0 Gy in 39 fx (2.0 Gy/fx) | 8 weeks | 81.25 Gy | 92.4% | 4.8% |
| Moderate Hypofractionation | 60.0 Gy in 20 fx (3.0 Gy/fx) | 4 weeks | 77.14 Gy | 89.6% | 4.5% |
| Ultra-Hypofractionated SBRT | 36.25 Gy in 5 fx (7.25 Gy/fx) | 1.5 - 2 weeks | 90.63 Gy | 94.1% | 5.4% |
Clinical Treatment Summary Ready for Export
Linear-quadratic parameters, cumulative BED/EQD2 metrics, and delivery timeline timestamps.